VIDA provides quality, quantitative CT imaging analysis for all major lung and respiratory diseases to streamline clinical trials with leading protocols.
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. This clearance further validates the quality and clinical efficacy of the company’s artificial intelligence (AI)-powered precision imaging and analytics solutions.
The addition of deep learning...
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has onboarded more than 1,000 sites globally in its VIDA network of imaging sites. This network is connected through the VIDA Intelligence Portal, a cloud native AI-enabled platform that drives efficiencies in clinical trial imaging operations by optimizing site recruitment and onboarding, staff training, image data collection, data quality, data curation, and more.
“Accelerated by the success of our VIDA Intelligence Portal,...
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage VIDA’s unique AI-enabled biomarker generation services and decades of validated techniques with previously generated...
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, has announced it has secured financing as it scales up to support strong demand for its VIDA Intelligence Portal, an AI-powered solution that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality. Since launching this latest addition to VIDA`s platform five months ago, demand has driven VIDA`s network to reach more than 1,000 sites, leading to substanti...
VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. Leveraging a powerful AI engine, the portal automates cumbersome and time sensitive tasks such as subject anonymization and quality control workflow processes.
Clinical trial operations...
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, today announced a new strategic partnership with Peoria, Illinois-OSF HealthCare that will make VIDA Insights available to care teams across the organization. VIDA and its comprehensive, lung intelligence solutions continue to gain traction among integrated delivery network (IDN) health care providers across the country.
The agreement provides OSF HealthCare, an integrated Catholic health system with 14 hospitals,...
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has signed an agreement with UnityPoint Health to implement VIDA’s AI-powered lung intelligence and imaging solutions across the UnityPoint Health system.
UnityPoint Health is one of the nation’s leading integrated delivery networks, with 21 hospitals and more than 400 physician clinics in both metropolitan and rural communities across Iowa, western Illinois, and southern Wisconsin....
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it is has appointed Karen Drexler to its board of directors, further expanding the company’s leadership strength in digital health technology.
Drexler’s appointment comes at a critical time in healthcare, as the world continues to address the potential long-term lung health implications of the COVID-19 pandemic. VIDA, with its suite of AI-powered lung intelligence solutions and analytics,...
Customer reviews
No reviews were found for VIDA Discovery Software. Be the first to review!
